Angel One - Share Market Trading and Stock Broking
Open Demat AccountLogin

Sun Pharmaceutical Industries Share Price Live

SUNPHARMA

Large Cap | Pharmaceuticals

₹ 1799.20

-45.10(2.45%)

Live Sun Pharmaceutical Industries Share Price Chart

Sun Pharmaceutical Industries Performance

Days Range

Previous Close₹1,844.30
Open₹1,844.3
Volume1,00,58,090
Day's Range₹1,785.30 - ₹1,852.80
52W Range₹1,548.00 - ₹1,916.60
Market Cap₹4,32,096.23 Cr

Sun Pharmaceutical Industries Fundamentals

ROCE(TTM)17.33
P/E Ratio (TTM)37.54
P/B Ratio5.17
Industry P/E33.73
Debt to Equity0.06
ROE13.74
EPS (TTM)52.01
Dividend Yield0.89
Book Value348.31
Face Value1
ROCE(TTM)17.33
P/E Ratio (TTM)37.54
P/B Ratio5.17
Industry P/E33.73
Debt to Equity0.06
ROE13.74
EPS (TTM)52.01
Dividend Yield0.89
Book Value348.31
Face Value1

Sun Pharmaceutical Industries Financials

Jun 2025Sep 2025Dec 2025Mar 2026
Net Sales13,786.0714,405.2215,469.0714,559.75
Expenses10,250.2910,680.7611,304.3811,433.06
Profit before tax3,172.774,167.614,227.163,551.34
Operating Profit2,302.623,137.093,401.092,723.72
Net Profit2,302.623,137.093,401.092,723.72
EPS in Rs12.8713.0016.0111.30

Sun Pharmaceutical Industries Shareholding Pattern

Held byMar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Promoters54.48%54.48%54.48%54.48%54.48%
Flls17.96%17.26%16.55%16.12%15.93%
Dlls18.7%19.5%20.23%20.82%21.11%
Public8.87%8.77%8.73%8.58%8.48%

About Sun Pharmaceutical Industries

History

Sun Pharmaceutical Industries Ltd was incorporated in 1983 and began its operations in Kolkata with only 5 products to treat psychiatric ailments. They built a compact manufacturing facility for tablets/capsules at Vapi, Gujarat. An administrative office was opened in Mumbai in 1986. By 1987, they had been marketing their products nationwide. In the late 1980s, the company began exporting their products to neighbouring countries. In 1998, they established their first research centre, SPARC, to create a strong base for product development in the following years. In 1994, the company became listed via an IPO. In 2016, Sun Pharma and AstraZeneca Pharma India Ltd began a partnership for the distribution of an innovative Type 2 diabetes medicine named dapagliflozin in India. In the same year, Sun Pharma and the International Centre for Genetic Engineering and Biotechnology (ICGEB) also agreed to together develop a novel drug for dengue. During in 2021, Sun Pharma launched 96 products in the domestic market. It also supplied drugs like Remdesivir, Favipiravir, Hydroxychloroquine (HCQS), and Liposomal Amphotericin B for the treatment of COVID-19 as well as the anti-epileptic Brevipil (Brivaracetam) and FluGuard (Favipiravir).  

Business Segments

Sun Pharmaceutical Industries Ltd, along with its subsidiaries and associates, is the fourth largest generic pharma company. As of September 2023, the company has a robust global presence with 43 manufacturing facilities across the world. India and the US are two major markets, accounting for more than 60% of the company's revenue in FY 2023. They also have a strong presence in emerging markets such as Russia, Romania, South Africa, Brazil, Mexico, etc.  In terms of the share of disease-wise drugs in the total revenue from India in FY 2023, Cardiology solutions contribute 18%, Neuro-Psychiatry 16%, and Gastroenterology 12%, among others. The company manufactures a wide range of pharmaceutical formulations for chronic and acute therapies. This covers generics, complex products, antiretrovirals (ARVs), Active Pharmaceutical Ingredients (APIs) and intermediates, among others. The portfolio is made of over 2,000 high-quality products with multiple dosage forms, including tablets, capsules, injectables, sprays, inhalers, ointments, etc.  Sun Pharmaceutical Industries invests around 7-8% of its global revenue every year in research. The R&D capabilities span the development of differentiated products, such as liposomal products, lyophilised injections, inhalers, and nasal sprays, alongside controlled-release dosage forms. Some of the subsidiaries of Sun Pharmaceuticals include Sun Pharma Laboratories Limited, Sun Pharma Holdings, Sun Pharma Distributors Limited, among others.

Key Personnel

Dilip Shanghvi, Founder and Managing Director Mr. Shanghvi is the founder of Sun Pharmaceutical Industries Ltd. with extensive experience in the pharmaceutical industry. Starting out as a first-generation entrepreneur, Mr. Shanghvi is today also the Chairman of Sun Pharma Advanced Research Company Ltd and of the Shantilal Shanghvi Foundation. 

Corporate Actions

Bonus Shares Sun Pharmaceuticals has issued bonus shares once in 2013 at a ratio of 1:1. Stock Split The face value of the stock had been split once in 2010, from ₹5 to ₹1. Buyback  The company performed a buyback of shares in July 2016. Mergers and Acquisitions
  • In FY 2023, Sun Pharma acquired Concert Pharma. Inc. which was developing a treatment for Alopecia Areata.
  • Since 2012, the company has acquired 6 companies in order to scale up their operations. Their past acquisitions include Dusa Pharma, Taro Pharma, URL Pharma, Ranbaxy Laboratories, Biosintez and Pola Pharma.

Management Outlook

The management expects global pharmaceutical spending to grow by a CAGR of 3-6% between 2023 and 2027 to reach a total market size of roughly US$ 1.9 trillion. The company also expects the global specialty pharmaceutical solutions market to grow. It already commands 43% of the total pharmaceutical spending globally as of 2022 and is expected to grow to 56% by 2027. Sensing the above shifts, Sun Pharma has continued to expand its global specialty offerings, with a focus on the areas of dermatology, ophthalmology and onco-dermatology. Their investments are designed to acquire products through in-licensing/acquisitions and in-house R&D and build front-end commercial infrastructure for these products.

Parent Organisation
Sun Pharma
Managing Director
Kirti Wardhaman Ganorkar
Founded
1993
NSE Symbol
SUNPHARMA

Sun Pharmaceutical Industries Share Price History

ParticularsDetails
5-Year % change in Sun Pharmaceutical Industries share price302.28%
5-Year Highest in Sun Pharmaceutical Industries share price₹ 1960.35
5-Year Lowest in Sun Pharmaceutical Industries share price₹ 434.25
1-Year % change in Sun Pharmaceutical Industries share price20.04%
1-Year Highest in Sun Pharmaceutical Industries share price₹ 1960.35
1-Year Lowest in Sun Pharmaceutical Industries share price₹ 1377.2

Peer Comparison

StocksLTP (₹)Market Cap (cr)52 Week Low-High (₹)
Divis Laboratories Ltd6,667.0
-130.50 (-1.92%)		₹1,76,807.385,636.5 - 7,071.5View Stocks
Torrent Pharmaceuticals Ltd4,410.8
-127.00 (-2.80%)		₹1,48,718.003,102.0 - 4,712.9View Stocks
Cipla Ltd1,401.0
-17.20 (-1.21%)		₹1,12,970.911,165.7 - 1,673.0View Stocks
Dr Reddys Laboratories Ltd1,303.5
-15.50 (-1.18%)		₹1,08,751.631,148.4 - 1,379.7View Stocks
Zydus Lifesciences Ltd1,077.7
-8.10 (-0.75%)		₹1,08,441.84835.5 - 1,115.5View Stocks
Lupin Ltd2,267.7
-8.70 (-0.38%)		₹1,03,900.021,836.8 - 2,494.0View Stocks

Sun Pharmaceutical Industries Latest News

Live Market Data: Sun Pharmaceutical Industries Ltd Share Price Drops -2.75% Today

Sun Pharmaceutical Industries Ltd's share price has fallen by -2.75%, presenting both challenges and opportunities for investors. As of now, it's trading at 1793.50, and market participants are assessing the implications. The stock has a PE ratio of 38.4600, an ROE of 13.7363 and a debt to equity ratio of 0.0554.

Live Updates: Sun Pharmaceutical Industries Ltd Stock Loses Ground Today, Falls -0.47%

Sun Pharmaceutical Industries Ltd experienced a -0.47% dip in its share price and is currently trading at 1835.60. The stock has a PE ratio of 38.4600, an ROE of 13.7363 and a debt to equity ratio of 0.0554.

Sun Pharmaceutical Industries Ltd Share Price in Red Today, Down -0.47%

Sun Pharmaceutical Industries Ltd shares experienced a -0.47% reduction, with the current market price at 1835.60. Investors are carefully considering their positions and seeking insights into the stock's future performance.

Sun Pharmaceutical Industries Ltd FAQs

Sun Pharmaceutical Industries Ltd (SUNPHARMA) share price as of May 29, 2026, on NSE is Rs 1799.2 (NSE) and Rs 1799.2 (BSE) on BSE.
Yes, You can buy Sun Pharmaceutical Industries Ltd (SUNPHARMA) shares by opening a Demat account with Angel One.
Sun Pharmaceutical Industries Ltd (SUNPHARMA) share can be bought through the following modes:
1. Direct investment: You can buy Sun Pharmaceutical Industries Ltd (SUNPHARMA) shares by opening a Demat account with Angel One.
2. Indirect investment: The indirect method involves investing through ETFs and Mutual Funds that offer exposure to Sun Pharmaceutical Industries Ltd (SUNPHARMA) shares.
The promoters of Sunpharma are Shanghvi Finance Private Limited, Dilip.S.Shanghvi, Dilip Shantilal Shanghvi, Aditya Medisales Limited, Raksha S.Valia and Sudhir V. Valia.
Sunpharma provides a range of over-the-counter (OTC)/consumer healthcare products.
Being a maker of over-the-counter (OTC)/consumer healthcare products including Faringosept (sore throat), Revital (vitamins) and Volini (topical analgesics). These are a few of their flagship OTC brands that are marketed globally.
The market cap of Sun Pharmaceutical Industries is Rs. 432096.23 Cr. as of 30/05/2026.
The P/E ratios of Sun Pharmaceutical Industries is 37.54 as of 30/05/2026.
The PB ratios of Sun Pharmaceutical Industries is 5.17 as of 30/05/2026.

Related News

View All
CCI Clears Creation of JV Company Between Mercuria Energy Netherlands and Tata International Singapore

Share Market

CCI Clears Creation of JV Company Between Mercuria Energy Netherlands and Tata International Singapore

May 27, 2026
Jindal India Completes ₹1,500 Crore Expansion Project in West Bengal with New Coating Facility

Share Market

Jindal India Completes ₹1,500 Crore Expansion Project in West Bengal with New Coating Facility

May 20, 2026
Consumer Goods Makers Including Hindustan Unilever and Dabur Expect Volume Led Growth as Inflation Eases

Share Market

Consumer Goods Makers Including Hindustan Unilever and Dabur Expect Volume Led Growth as Inflation Eases

February 24, 2026
Open Free Demat Account!
Join our 3.5 Cr+ happy customers